Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Myalgia, Mycoplasma infection, Pneumonia, SARS-CoV-2 test, Spondylitis
Clinical narrative: pneumoniae; severe inflammatory response, induced side of keen storm; exacerbation of thyroiditis; exacerbation of spondylitis; exacerbation of thyroiditis/exacerbation of spondylitis; Epstein-Barr; mycoplasma; severe muscle aches; unable to get out of bed and ambulate; Unable to carry out activities of daily living; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 56-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), on 25Feb2021 at 09:00 as dose 2, single (Lot number: EN5318) at the age of 56 years, in left leg for covid-19 immunisation. The patient's relevant medical history included: "Hashimoto's disease" (unspecified if ongoing); "rosacea" (unspecified if ongoing); "sleep apnea" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: bnt162b2 (Dose 1, Single, Lot Number: EL3302, Anatomical location: Arm Left, Vaccination time: 09:00), administration date: 04Feb2021, when the patient was 56-year-old, for COVID-19 immunisation. The following information was reported: EPSTEIN-BARR VIRUS INFECTION (non-serious) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "Epstein-Barr"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "Unable to carry out activities of daily living"; SPONDYLITIS (non-serious) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "exacerbation of spondylitis"; AUTOIMMUNE THYROIDITIS (medically significant) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "exacerbation of thyroiditis"; CONDITION AGGRAVATED (non-serious) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "exacerbation of thyroiditis/exacerbation of spondylitis"; MYCOPLASMA INFECTION (non-serious) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "mycoplasma"; PNEUMONIA (medically significant) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "pneumoniae"; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (medically significant) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "severe inflammatory response, induced side of keen storm"; MYALGIA (non-serious) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "severe muscle aches"; MOBILITY DECREASED (non-serious) with onset 25Feb2021 at 20:00, outcome "recovered with sequelae", described as "unable to get out of bed and ambulate". The events "pneumoniae", "severe inflammatory response, induced side of keen storm", "exacerbation of thyroiditis", "exacerbation of spondylitis", "exacerbation of thyroiditis/exacerbation of spondylitis", "epstein-barr", "mycoplasma", "severe muscle aches", "unable to get out of bed and ambulate" and "unable to carry out activities of daily living" required physician office visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Post vaccination.  Clinical course: It was reported that the patient didn't had any other vaccine in four weeks. Prior vaccination, no covid-19 test was done. No known allergies were reported. Events were recovered with lasting effects.; Sender's Comments: Based on the limited information provided in this case, a contributory role of the suspect product BNT162b2 (COMIRNATY) to the reported events cannot be excluded. There is very limited information provided in this report. Case will be reassessed upon receipt of additional information.,Linked Report(s) : US-PFIZER INC-202300304291 same reporter, patient and product; different dose and events;